In an institutionalized patient already on multiple antipsychotics for aggressive behavior, what non‑benzodiazepine, non‑antipsychotic medication can be used to manage anger?

Mood Stabilizers Are the Primary Non-Benzodiazepine, Non-Antipsychotic Option for Anger Management

For an institutionalized patient already on multiple antipsychotics with persistent aggressive behaviors, divalproex sodium (Depakote) is the recommended first-line non-benzodiazepine, non-antipsychotic medication, starting at 125 mg twice daily and titrating to therapeutic blood levels of 40-90 mcg/mL 1.

Algorithmic Approach to Medication Selection

First-Line: Divalproex Sodium (Depakote)

• Start: 125 mg twice daily
• Target: Therapeutic blood level 40-90 mcg/mL
• Rationale: Guidelines specifically identify this as "generally better tolerated than other mood stabilizers" for control of severe agitated, repetitive, and combative behaviors 1
• Monitoring: Liver enzyme levels, platelets, PT/PTT as indicated
• Evidence: Demonstrated 70% reduction in aggression scores in adolescents with explosive temper 2

Second-Line: Alternative Mood Stabilizers

If divalproex is ineffective or not tolerated:

Lithium carbonate

• Effective for pathologic aggression across multiple populations 3
• Requires therapeutic monitoring
• Particularly useful if underlying mood instability is suspected

Carbamazepine (Tegretol)

• Initial: 100 mg twice daily
• Titrate to therapeutic level: 4-8 mcg/mL
• Caution: More problematic side effects than divalproex 1
• Requires CBC and liver enzyme monitoring

Third-Line: Trazodone

• Start: 25 mg per day
• Maximum: 200-400 mg per day in divided doses
• Listed as a "mood-stabilizing (antiagitation) drug" in guidelines 1
• Caution: Use carefully in patients with premature ventricular contractions
• Less robust evidence than mood stabilizers but useful alternative

Fourth-Line: Beta-Blockers (Propranolol)

• Effective across multiple neuropsychiatric conditions including dementia, brain injury, schizophrenia, and organic brain syndrome 4
• Major limitation: Marked hypotension and bradycardia at higher doses
• Requires careful cardiovascular monitoring
• Consider when other options have failed

Critical Considerations

Why Not Buspirone?

While buspirone is mentioned in guidelines as a non-benzodiazepine anxiolytic, it has significant limitations:

• Only useful for mild to moderate agitation 1
• Takes 2-4 weeks to become effective
• Your patient has severe aggression requiring multiple antipsychotics, making buspirone inadequate

The Antipsychotic Polypharmacy Problem

The patient is already on multiple antipsychotics, which represents a concerning practice pattern. Guidelines explicitly warn that "polypharmacy may further cloud these already complicated cases" 3. Before adding another medication:

• Verify the antipsychotics are optimally dosed
• Consider whether consolidating to a single, more effective antipsychotic (particularly clozapine for treatment-resistant aggression) might be more appropriate than adding adjunctive agents

Monitoring Requirements

Regardless of which mood stabilizer you choose:

• Establish baseline aggression measures before starting
• Allow adequate trial duration (mood stabilizers require weeks to months for full effect)
• Monitor therapeutic drug levels
• Track liver function and hematologic parameters
• Document specific target behaviors

Common Pitfalls to Avoid

1. Starting too high: Begin with low doses and titrate slowly to minimize side effects and improve tolerability
2. Inadequate trial duration: Mood stabilizers require 4-8 weeks minimum for adequate assessment 1
3. Skipping therapeutic drug monitoring: Blood levels are essential for both efficacy and safety
4. Adding medications without reassessing the base regimen: Multiple antipsychotics may themselves be contributing to behavioral dyscontrol through akathisia or other side effects

Evidence Quality Note

The guideline evidence 1 dates from 2002 but represents the most comprehensive algorithmic approach to non-benzodiazepine, non-antipsychotic options for aggression. More recent guidelines 3 from 2007 confirm these recommendations, particularly emphasizing mood stabilizers (divalproex and lithium) for aggressive behavior. The 2023 meta-analysis 5 supports that non-pharmacological interventions should remain primary, but when pharmacological augmentation is needed beyond antipsychotics, mood stabilizers represent the evidence-based choice.